BioInformant Logo - As Featured On

Your Global Leader in Stem Cell Industry Data


Are you managing a stem cell company or cord blood bank?

We can assist you with your strategic goals, because we specialize in your industry niche. BioInformant is the only company that has specifically tracked the stem cell sector since it emerged.

Because there are hematopoietic stem cells in cord blood and mesenchymal stem cells in cord tissue, we’ve also been tracking the cord blood industry since 2006.

BioInformant has been featured on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, the California Institute of Regenerative Medicine (CIRM), and more.

To receive critical stem cell and cord blood industry alerts about scientific advancements, patent challenges, key mergers, case law changes, clinical trial advances, and more, sign-up below.  We will never share your information with anyone, and you can opt-out at any time.

No spam, ever. Just great stuff that will keep you informed about your marketplace.

Wondering whether to join? This makes sense, especially if this is your first time visiting. See what our clients have to say about us and then make your decision…


“I am now truly enlightened. You are awesome! I must say it has been an absolute pleasure working with you folks. You will always get a great customer recommendation from me.”

John Jaskowiak
Vice President, Angiocrine Bioscience
www.angiocrinebioscience.com
 

“I was truly impressed by BioInformant. You can trust BioInformant to do things right and generate greater awareness of your technology. They are the go-to resource for stem cell researchers and companies looking for trustworthy stem cell business information and marketing support.”

Dr. William Frey II
Founder and Co-Director of the Alzheimer’s Research Center
www.alzheimersinfo.org

“The BioInformant team was great to work with. The cord blood report we claimed was comprehensive and informative and the team was extremely responsive to all of our questions. I would highly recommend them to anyone interested in learning more about the cord blood and cord tissue markets.”

Kevin Cox
Private Equity Analyst, Audax Group
www.audaxgroup.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>